Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm
Phase 3
Recruiting
- Conditions
- Condition 1: COVID-19. Condition 2: Coronavirus (COVID-19)-induced pneumonia.Pneumonia due to SARS-associated coronavirusU07.1: COVID-19, virus identifiedJ12.81U07.1
- Registration Number
- IRCT20200317046797N3
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Respiratory rate more than 30
PaO2/FiO2 less than 300 mm Hg
Positive PCR for COVID -19
Age 18-65 year
Exclusion Criteria
Sensitivity to IVIG
Pregnancy
IgA deficiency syndrome
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie IVIG's anti-inflammatory effects in SARS-CoV-2-induced cytokine storms?
How does IVIG compare to corticosteroids in managing severe COVID-19 pneumonia with hyperinflammation?
Which biomarkers are associated with IVIG response in patients with cytokine storm syndrome from SARS-CoV-2 infection?
What are the potential adverse events of IVIG therapy in critical COVID-19 cases and how are they managed?
Are there combination therapies involving IVIG and antiviral agents for treating cytokine storm in SARS-CoV-2 pneumonia?